Welcome to our dedicated page for Amedisys SEC filings (Ticker: AMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Complex Medicare reimbursement tables, shifting hospice regulations, and acquisition footnotes can make Amedisys, Inc. (NASDAQ: AMED) filings feel like a maze. If you have ever asked, “How do I locate the labor-cost breakout in Amedisys’ annual report 10-K?” or “Where are Amedisys insider trading Form 4 transactions listed in real time?”, this page is built for you.
Stock Titan’s AI-powered engine turns every AMED disclosure—10-K, 10-Q, 8-K, DEF 14A, S-8, and more—into clear, searchable insights. Our algorithms read the footnotes so you can quickly:
- Track clinician head-count trends inside the latest Amedisys quarterly earnings report 10-Q filing.
- Review hospice cap exposure highlighted in the Amedisys annual report 10-K simplified.
- Receive instant alerts for every Amedisys Form 4 insider transactions real-time, including executive stock sales ahead of rate-setting announcements.
- See board-level pay packages with a single click in the Amedisys proxy statement executive compensation.
Each document includes an AI summary that explains material events, from acquisition-related goodwill in an 8-K to segment margin shifts buried deep in MD&A. No more skimming hundreds of pages—our expert analysis highlights reimbursement changes, patient-census data, and cash-flow details investors use to benchmark post-acute providers.
Whether you’re comparing home-health operators or trying to understand “Amedisys insider trading Form 4 transactions”, this hub delivers every filing the moment it hits EDGAR, already decoded. Spend your time making decisions, not finding disclosures.
Amedisys Inc (AMED) submitted a Form 25 notification indicating the removal or withdrawal of a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer name, Nasdaq as the exchange and provides the company's Baton Rouge address and phone number. The form references rule provisions under 17 CFR 240.12d2-2 and states the Exchange and/or the issuer have complied with applicable procedures for striking the class from listing or voluntary withdrawal. The copy provided does not include which specific checkbox was marked, the class of securities affected, or an authorized signature and date.
Amedisys Inc (AMED) submitted a Form 25 notification indicating the removal/withdrawal of a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing lists the issuer name, Nasdaq as the exchange, and the issuer's Baton Rouge address and phone number. The form states the Exchange and the Issuer have complied with the applicable rules governing withdrawal, but the specific rule box selected and any signature or date details are not present in the provided text.
Amedisys, Inc. is deregistering all unsold or unissued shares of its common stock that remain registered under several prior S-8 registration statements. The filing identifies each S-8 by registration number, the employee plan tied to that registration (including stock option plans, directors' plan, omnibus incentive plans and an employee stock purchase plan) and the specific number of shares that had been registered under each statement.
Amedisys filed a post-effective amendment to deregister unsold or otherwise unissued shares of its common stock that remained registered under multiple previously filed S-8 registration statements. The filing lists each S-8 by file number, original filing date and the number of shares covered under various employee plans, including stock option plans, omnibus incentive plans and an employee stock purchase plan. The document is signed by the CEO.
Amedisys, Inc. submitted a post-effective amendment to deregister all registered but unsold or otherwise unissued shares of its common stock that remained under multiple previously filed S-8 registration statements. The filing lists eight prior S-8 registration statements and the number of shares each covered, including plans such as the 1998 Stock Option Plan, Directors' Stock Option Plan, Employee Stock Purchase Plan, 2008 Omnibus Incentive Compensation Plan and the 2018 Omnibus Incentive Compensation Plan. The document is signed by the CEO, Richard Ashworth.
Amedisys, Inc. has submitted a post-effective amendment to deregister all unsold or unissued shares of its common stock that remained registered under several previously filed S-8 registration statements. The filing lists eight S-8 registrations spanning 1998 through 2018 and specifies the originally registered share amounts for each plan, including employee stock purchase and omnibus incentive compensation plans. The company states that the listed share counts do not reflect interim corporate actions such as stock splits.
Amedisys, Inc. submitted a notice to deregister shares of its common stock that remain registered but unsold or otherwise unissued under a series of previously filed S-8 registration statements. The filing lists eight prior S-8 registrations covering employee stock purchase and various stock option and omnibus incentive plans, with registered amounts ranging from 75,000 to 4,100,000 shares per filing. The company states that the listed share numbers do not reflect interim corporate actions such as stock splits and identifies Richard Ashworth as President and CEO signing the notice.
AMEDISYS, Inc. filed a post-effective amendment to deregister all unsold or otherwise unissued shares of its common stock that remained registered under several prior S-8 registration statements. The filing lists eight historical S-8 registration numbers and the original share amounts registered under each plan, ranging from 75,000 to 4,100,000 shares, including registrations for employee purchase, directors' options and omnibus incentive plans. The action removes those previously registered but unsold shares from registration.
Amedisys, Inc. filed a post-effective amendment to deregister unsold or otherwise unissued shares previously registered on multiple S-8 registration statements. The filing identifies eight prior S-8 filings covering specific share amounts under various employee equity plans, including totals of 1,000,000; 1,425,000; 75,000; 2,500,000; 1,862,459; 4,100,000; 1,500,000; and 2,500,000 shares. The company certifies that these shares are no longer registered under those filings as of the date presented and the notice is signed by the CEO.
Amedisys, Inc. submitted a post-effective amendment to deregister any and all shares of its common stock that remain registered but unsold or otherwise unissued under multiple previously filed S-8 registration statements. The filing lists the specific S-8 files and original share amounts for plans including employee stock purchase and omnibus incentive plans.
The notice clarifies that the listed share counts do not account for interim corporate actions such as stock splits.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
